Krystal BiotechFRA:4KB +3.23%58 Altman Z-Score is 57.37 as of Jun. 27, 2026, which is 24% above its 10-year median of 46.24. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €262.63 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 934 Biotechnology companies, Krystal Biotech ranks better than 96.04% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 56.41 is strong.
Krystal Biotech has a Altman Z-Score of 57.37, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Krystal Biotech's Altman Z-Score or its related term are showing as below:
FRA:4KB'
s Altman Z-Score Range Over the Past 10 Years
Min: 21.91 Med: 46.24 Max: 138.51
Current: 56.41
During the past 10 years, Krystal Biotech's highest Altman Z-Score was 138.51. The lowest was 21.91. And the median was 46.24.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Krystal Biotech Altman Z-Score Related Terms
Krystal Biotech Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs NUVL, PRAX, TECH: Altman Z-Score Comparison
For the Biotechnology subindustry, Krystal Biotech's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Krystal Biotech's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.6528
+
1.4
*
0.0573
+
3.3
*
0.1475
+
0.6
*
92.8702
+
1.0
*
0.2969
=
57.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Krystal Biotech (FRA:4KB) has a Altman Z-Score of 57.37 as of Jun. 27, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Krystal Biotech and its competitors. This is 24% above median its historical median of 46.24. Over the past decade, Krystal Biotech's Altman Z-Score has ranged from 21.91 to 138.51. According to the industry distribution chart, Krystal Biotech ranks #37 out of 934 companies in the Biotechnology industry, placing it in the top 4%.
Is Krystal Biotech's Altman Z-Score too high?
Krystal Biotech's current Altman Z-Score of 57.37 is 24% above median its 10-year median of 46.24. Over the past 10 years, this metric has ranged from a low of 21.91 to a high of 138.51. The Biotechnology industry median Altman Z-Score is 2.63. Krystal Biotech's value of 57.37 is 2085.5% above this industry median. Based on the distribution chart, Krystal Biotech ranks #37 out of 934 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Altman Z-Score compare to NUVL and PRAX?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #37 out of 934 companies for Altman Z-Score. This places Krystal Biotech in the top 4% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.63. Krystal Biotech's value of 57.37 is 2085.5% above this benchmark. Historically, Krystal Biotech's own Altman Z-Score has ranged from 21.91 to 138.51 over the past decade. While the company's 10-year median is 46.24 vs. the industry median of 2.63, Krystal Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.63, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current Altman Z-Score of 57.37 is 2085.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Krystal Biotech and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current Altman Z-Score is 57.37, which is 24% above median its own 10-year median of 46.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €262.63, compared to a current price of €313.40 — trading 19.3% above its estimated fair value. The current Altman Z-Score is 57.37, which is 24% above median its 10-year median of 46.24 and 2085.5% above the Biotechnology industry median of 2.63. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Altman Z-Score is 57.37 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €313.40 is trading 19.3% above its estimated GF Value™ of €262.63.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
Altman Z-Score: 57.37 (24% above median its 10-year median of 46.24)
GF Value™: €262.63 vs. price of €313.40 (19.3% above fair value)
Industry Position: 2085.5% above the Biotechnology median (#37 of 934)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score
Get the complete analysis for FRA:4KB
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
